ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Uniqure NV

Uniqure NV (UQ1)

17.425
-0.145
(-0.83%)
Closed January 05 3:00PM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
17.425
Bid
17.14
Ask
17.705
Volume
236
17.25 Day's Range 17.89
3.548 52 Week Range 17.89
Previous Close
17.57
Open
17.55
Last Trade
25
@
17.364999
Last Trade Time
Average Volume (3m)
1,749
Financial Volume
-
VWAP
-

UQ1 Latest News

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease ~ Achieved statistically significant...

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.7354.4038346315216.6917.8916.2248516.49761004DE
411.269183.0571799876.15617.896.154426114.61908448DE
1212.467251.4521984674.95817.894.958174912.5690584DE
2613.561350.9575569363.86417.893.54818159.69399969DE
5211.035172.691705796.3917.893.54812768.44272565DE
156-0.525-2.9247910863517.9525.613.5488528.50296085DE
260-14.035-44.612205975831.4632.783.5485819.70057369DE

UQ1 - Frequently Asked Questions (FAQ)

What is the current Uniqure NV share price?
The current share price of Uniqure NV is 17.425 €
What is the 1 year trading range for Uniqure NV share price?
Uniqure NV has traded in the range of 3.548 € to 17.89 € during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
0S6Cerence Inc
18.972 €
(145.34%)
89.94k
CY9DMicrobot Medical Inc
2.11 €
(89.07%)
24.21k
RV0Torrent Gold Inc
0.138 €
(73.58%)
1.23k
7CCCheckCap Ltd
1.76 €
(55.75%)
6.55k
34Q0Quantum eMotion Inc
0.985 €
(53.91%)
1.62M
7DBDiamondback Energy Inc
9.7176 €
(-94.02%)
800
FASFastenal Co
9.7358 €
(-85.95%)
2.13k
1UR1Bee Vectoring Technologies International Inc
0.003 €
(-45.45%)
300.18k
B4T0CuFe Ltd
0.0045 €
(-25.00%)
1
H5EHelma Eigenheimbau Ag
0.0766 €
(-23.40%)
751
PF8European Lithium Limited
0.0264 €
(8.20%)
5.76M
3CPXiaomi Corporation
4.597 €
(7.34%)
3.95M
D7GNel ASA
0.247 €
(2.66%)
2.33M
J9AVERSES AI Inc
1.352 €
(0.00%)
1.67M
34Q0Quantum eMotion Inc
0.985 €
(53.91%)
1.62M

Discussion

View Full Feed
dragoon76 dragoon76 3 minutes ago
Seriously though...what is your purpose being here? You and your crew repeatedly tell us that nothing is coming back. Why? What's the logic in that if none of us have any control over the situation...OR DO WE and we just don't know it, yet?
COOP
OMOLIVES OMOLIVES 3 minutes ago
You should really stop with the Adverts' man. EOM
Nick2424 Nick2424 4 minutes ago
What happened to the expected California composting contracts expected by end of 2024? You need to talk about it. Just another reason for investors to lose trust if you don't.

Why are there weekly meetings with the PR team. Why don't they start doing stuff to make the stock go up. Do
DUTV
boston745 boston745 5 minutes ago
In the post referenced at the end of this post, i say i think i understand what Musks role is for the DoD & intelligence community. However after watching a show called Salvation again, i picked up on something i hadnt noticed before. Before i get into that, here is a quote from that post:
HokieHead HokieHead 5 minutes ago
Lmfao, keep watching.
TWOH
ron_66271 ron_66271 7 minutes ago
Your Statement Makes No Sense.

“Link where anyone else shows that JPM failed because of Lehman.”

JPM didn’t fail because of Lehman’s.

JPM failed because JPM wrote more Derivative Contracts than JPM could cover.
Hint; Bears Sterns.

JP
JPM
marcis marcis 10 minutes ago
Thanks
Nice to know, not your position, but approach

⭐️
HOMU
JusDePomme JusDePomme 11 minutes ago
I remember raging bull and all stock board!
AFFU
Hummingbird2 Hummingbird2 11 minutes ago
https://x.com/kshaughnessy2/status/1875963962795139215
GTII
Shawonsarker84 Shawonsarker84 13 minutes ago
$HMBL X is looking good! Lots of traders want to get in early. NoMoDo mentioned that 32B OS doesn't concern when the float runs clean. If there is no further dilution, this train can not be stopped.

LFG #HMBL 2025! This is a once in a lifetime chance to get in early, and now is the t
HMBL
JERSEYHAWG JERSEYHAWG 14 minutes ago
Ok

On my end

Glad all this is over
Now if Lehman would just follow suit and get over soon to


I would be eternally gratefull for it to be over
LEHNQ
alidare alidare 16 minutes ago
One week closer to fully operational corn processing plant.

Love some of these yellow corn chips.

Corny times.

AABB
joyceschoice joyceschoice 17 minutes ago
Your opinion or can you show me proof? Link where anyone else shows that JPM failed because of Lehman. I agree JPM screwed Lehman at the last minute for advantage. Pretty much like many of the posters here would have done if that opportunity to kill would have been available for your benefit.
JPM
GoodGuyBill GoodGuyBill 17 minutes ago
my earliest shares were $4 - $6...
NWBO
Koan Koan 18 minutes ago
Everyone knows what this is about.

The three companies:

1. BioAmber Inc. - parent company (where the shares are)
2. BioAmber Sarnia - subsidiary
3. BioAmber Canada - subsidiary

BioAmber Inc. the parent company, BioAmber Sarnia and BioAmber
tdbowieknife tdbowieknife 19 minutes ago
Ok... It "trades" on two different markets, controlled by two different regulators, in two different Countries...

Wow....

Worried a bit??

..


.
TWOH
getmoreshares getmoreshares 19 minutes ago
COIN UP!!!!!!!!
CGAC
getmoreshares getmoreshares 20 minutes ago
i do not reveal my holding amounts-- will say-- did not sell a single share(all holdings) last year-- have been adding many positions all year. I do NOT FLIP- the TAX man gets enough.
HOMU
marcis marcis 20 minutes ago
OTCMARKETS will no longer require attorney letter for PINK current Status as of 01/31/25. Instead, a Management Certification will be required.
RDAR
MartinLutherKing MartinLutherKing 20 minutes ago
RNAZ microRNA technology was recognized with the 2024 Nobel Prize in Physiology and Medicine
TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer with 2.3Million market cap with 696K outstanding shares
RNAZ
Nerdy1 Nerdy1 21 minutes ago
💯 agree I believe that this will all be revealed and this will be one of the most interesting case studies in Business schools in the future. But in the moment we must fight. What is to stop the government from just taking them over again? What is to stop them from taking over other companie
FNMA
govprs govprs 21 minutes ago
I wasn't sure all of December but I feel more sure now.  Btw  I'm speculating we might see a series of PRs thru March.   So much in play now.  If I'm correct he will be chasing 😀
GDVM
MartinLutherKing MartinLutherKing 23 minutes ago
Is RNAZ An empty shell company
RNAZ